The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Relapse after HSCT 2021 | Management of relapse post-alloHSCT in patients with B-cell lymphoma
Peter Dreger, MD, Heidelberg University Hospital, Heidelberg, Germany, discusses treatment strategies that can be used in patients with B-cell lymphomas relapsing following allogeneic hematopoietic stem cell transplantation (alloHSCT). Prof. Dreger describes how radiotherapy alone or in combination with pathway inhibitors is an option for patients with aggressive B-cell lymphomas and large B-cell lymphomas that are insensitive to immunotherapy. He also comments on how biopsies can help identify druggable targets and how patients with other B-cell lymphomas, such as follicular lymphoma, can benefit from immunotherapy. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
